...
首页> 外文期刊>Journal of the International Aids Society >Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa
【24h】

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa

机译:在南非约翰内斯堡的一家大型公共诊所引入泰诺福韦后,治疗方案的耐久性提高

获取原文
   

获取外文期刊封面封底 >>

       

摘要

IntroductionIn April 2010, tenofovir replaced stavudine in public-sector first-line antiretroviral therapy (ART) in South Africa. The association of tenofovir with fewer side effects and toxicities compared to stavudine could translate to increased durability of tenofovir-based regimens. We evaluated changes over time in regimen durability at the Themba Lethu Clinic, Johannesburg, South Africa.MethodsThis was a cohort analysis of treatment-na?ve, non-pregnant adult patients initiated on ART between April 2004 and December 2011. First-line ART regimens before April 2010 consisted of stavudine or zidovudine with lamivudine and either efavirenz or nevirapine. Tenofovir was substituted for stavudine after April 2010. We evaluated the frequency and type of single-drug substitutions (excluding switches to second-line therapy). Cox models were used to evaluate the association of ART initiation year and antiretroviral drug type with single-drug substitutions in the first 12 months on treatment.ResultsOne thousand nine hundred and sixty-four (10%) substitutions occurred amongst 19,699 patients. Excluding 2004 (year of treatment roll-out), before 2010 one-year single-drug substitutions ranged from 10.0 to 13.1%. In 2011, well after integration of tenofovir, substitutions decreased to 5.6%. Single-drug substitution was lowest amongst patients on tenofovir (5.1%) versus zidovudine (11.3%), 30 mg stavudine (10.5%) or 40 mg stavudine (14.4%). Adjusted Cox models showed that patients initiating treatment between 2005 and 2010 (vs. 2011) had a twofold increased hazard of single-drug substitution, while those on zidovudine or stavudine had a two to threefold increase in single-drug substitution versus tenofovir patients in the first 12 months on ART.ConclusionsThe decline in single-drug substitutions is associated with the introduction of tenofovir. Tenofovir use could improve regimen durability and treatment outcomes in resource-limited settings.
机译:简介2010年4月,替诺福韦在南非的公共部门一线抗逆转录病毒疗法(ART)中替代了司他夫定。与司他夫定相比,替诺福韦具有更少的副作用和毒性,这可以转化为基于替诺福韦的方案的持久性提高。我们评估了南非约翰内斯堡Themba Lethu诊所随着时间推移方案治疗持久性的变化。方法这是一项对2004年4月至2011年12月间接受过ART治疗的初次接受治疗的未怀孕成年患者的队列分析。一线抗病毒治疗2010年4月之前的治疗方案包括司他夫定或齐多夫定与拉米夫定以及依非韦伦或奈韦拉平。替诺福韦在2010年4月之后替代了司他夫定。我们评估了单药替代的频率和类型(不包括改用二线治疗)。在治疗的前12个月中,使用Cox模型评估ART起始年和抗逆转录病毒药物类型与单药替代的相关性。结果19699例患者中发生了194例(10%)替代。不包括2004年(治疗推广年),2010年之前的一年期单药替代率在10.0%至13.1%之间。 2011年,在替诺福韦整合很久之后,取代率下降到5.6%。替诺福韦(5.1%)与齐多夫定(11.3%),30 mg司他夫定(10.5%)或40 mg司他夫定(14.4%)的患者中,单药替代最低。调整后的Cox模型显示,在2005年至2010年之间开始治疗的患者(与2011年相比),单药替代的风险增加了两倍,而齐多夫定或司他夫定的患者单药替代的风险是替诺福韦患者的2到三倍。前12个月是ART。结论单药替代品的减少与替诺福韦的引入有关。在资源有限的情况下,使用替诺福韦可以改善治疗方案的持久性和治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号